Company to maximize world-class EU-GMP operations, potentially opening future revenue- generating opportunities June 20, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”) or the (“Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, has submitted a request... Read more
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001
January 20, 2022
Ryan Allway January 20th, 2022 Psychedelics VANCOUVER, British Columbia, Jan. 20, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to... Read more
BetterLife Obtains TD-0148A Receptor Binding Data for IND-Enabling Pharmacology Studies
October 29, 2021
Ryan Allway October 29th, 2021 Psychedelics VANCOUVER, British Columbia, Sept. 29, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to... Read more
